Market Place
Sourcing Support
All News #Library
Biotech
Atea Pharma Reveals 2025 Financials And Business Update
05 Mar 2026 //
GLOBENEWSWIRE
Atea Pharma Showcases At-587`s Hepatitis E Virus Treatment
24 Feb 2026 //
GLOBENEWSWIRE
Atea Reports Data For Bemnifosbuvir + Ruzasvir At Liver Meeting
07 Nov 2025 //
GLOBENEWSWIRE
Atea Pharmaceuticals Reports Q2 2025 Results, Updates on Business
07 Aug 2025 //
GLOBENEWSWIRE
Atea Pharma Announces Positive Ph 2 Results for HCV Regimen
04 Dec 2024 //
GLOBENEWSWIRE
Atea Supports Bemnifosbuvir-Ruzasvir Combo for Hepatitis C at AASLD
15 Nov 2024 //
GLOBENEWSWIRE
Atea Pharmaceuticals to Present Hepatitis C Data at AASLD
30 Oct 2024 //
GLOBENEWSWIRE
Atea Shows Bemnifosbuvir-Ruzasvir HCV Combo Potential At EASL
22 May 2024 //
GLOBENEWSWIRE
Atea`s Bemnifosbuvir Safety Data at ESCMID Global 2024
29 Apr 2024 //
GLOBENEWSWIRE
Atea Pharma Presents Promising Bemnifosbuvir and Ruzasvir Combination Data
13 Nov 2023 //
GLOBENEWSWIRE
Atea to Present Bemnifosbuvir and Ruzasvir Data for Hepatitis C Virus
02 Nov 2023 //
GLOBENEWSWIRE
Atea Announces U.S. FDA Fast Track Designation Granted to Bemnifosbuvir
25 Apr 2023 //
GLOBENEWSWIRE
Atea Announces Presentation of Bemnifosbuvir Data Showing Reduced Hospitalizations for COVID-19 Patients
12 Apr 2023 //
GLOBENEWSWIRE
Atea Pharmaceuticals announces results of bemnifosbuvir for Covid-19
15 Mar 2023 //
CLINICAL TRIALS ARENA
New Data Showcasing Favorable Profile of Bemnifosbuvir for Treatment of COVID-19
08 Mar 2023 //
GLOBENEWSWIRE
Atea Presents Favorable Drug Interaction Profile of Bemnifosbuvir in PI Studies
23 Feb 2023 //
GLOBENEWSWIRE
Atea Pharmaceuticals to Present Data on Bemnifosbuvir Drug Interaction Profile
15 Feb 2023 //
GLOBENEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.